CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will issue a news release at 8:00 a.m. Eastern time on Wednesday, December 11, 2013 announcing top-line results of its global Phase 2b clinical trial comparing the company’s aldoxorubicin as a first-line treatment for advanced soft tissue sarcomas (STS) versus the widely used chemotherapeutic agent doxorubicin. The company will host a conference call beginning at 10:30 a.m. Eastern time December 11 to discuss those results and answer questions.
Help employers find you! Check out all the jobs and post your resume.
